BYTRITE 1.25MG CAPSULES

Main information

  • Trade name:
  • BYTRITE 1.25MG CAPSULES
  • Dosage:
  • 1.25 Milligram
  • Pharmaceutical form:
  • Capsule
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • BYTRITE 1.25MG CAPSULES
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0915/009/001
  • Authorization date:
  • 22-04-2005
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

ByTrite1.25mgCapsules.

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachhardcapsulecontains1.25mgramipril.

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Capsules,hard.

Opaquerichyellowcapandopaquewhitebody,hardgelatincapsules(No.4),printedinblackink93and7209on

opposingcapandbodyportionsofthecapsules.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Treatmentofhypertension.

Treatmentofrenaldisease:

Incipientglomerulardiabeticnephropathyasdefinedbythepresenceofmicroalbuminuria,

Manifestglomerulardiabeticnephropathyasdefinedbymacroproteinuriainpatientswithatleastone

cardiovascularriskfactor(seesection5.1),

Manifestglomerularnondiabeticnephropathyasdefinedbymacroproteinuria ≥3g/day(seesection

5.1).

Treatmentofsymptomaticheartfailure.

Secondarypreventionafteracutemyocardialinfarction:reductionofmortalityfromtheacutephaseofmyocardial

infarctioninpatientswithclinicalsignsofheartfailurewhenstarted>48hoursfollowingacutemyocardialinfarction.

4.2Posologyandmethodofadministration

Oraluse.

ItisrecommendedthatByTriteistakeneachdayatthesametimeoftheday.

ByTritecanbetakenbefore,withoraftermeals,becausefoodintakedoesnotmodifyitsbioavailability(seesection

5.2).

ByTritehastobeswallowedwithliquid.Itmustnotbechewedorcrushed.

Adults

Diuretic-Treatedpatients:

HypotensionmayoccurfollowinginitiationoftherapywithByTrite;thisismorelikelyinpatientswhoarebeing

treatedconcurrentlywithdiuretics.Cautionisthereforerecommendedsincethesepatientsmaybevolumeand/orsalt

depleted.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 1

Inhypertensivepatientsinwhomthediureticisnotdiscontinued,therapywithByTriteshouldbeinitiatedwitha1.25

mgdose.Renalfunctionandserumpotassiumshouldbemonitored.ThesubsequentdosageofByTriteshouldbe

adjustedaccordingtobloodpressuretarget.

Hypertension

Thedoseshouldbeindividualisedaccordingtothepatientprofile(seesection4.4)andbloodpressurecontrol.

ByTritemaybeusedinmonotherapyorincombinationwithotherclassesofantihypertensivemedicinalproducts.

Startingdose

ByTriteshouldbestartedgraduallywithaninitialrecommendeddoseof2.5mgdaily.

Patientswithastronglyactivatedrenin-angiotensin-aldosteronesystemmayexperienceanexcessivedropinblood

pressurefollowingtheinitialdose.Astartingdoseof1.25mgisrecommendedinsuchpatientsandtheinitiationof

treatmentshouldtakeplaceundermedicalsupervision(seesection4.4).

Titrationandmaintenancedose

Thedosecanbedoubledatintervaloftwotofourweekstoprogressivelyachievetargetbloodpressure;themaximum

permitteddoseofByTriteis10mgdaily.Usuallythedoseisadministeredoncedaily.

Treatmentofrenaldisease

Inpatientswithdiabetesandmicroalbuminuria:

Startingdose:

Therecommendedinitialdoseis1.25mgofByTriteoncedaily.

Titrationandmaintenancedose

Dependingonthepatient'stolerabilitytotheactivesubstance,thedoseissubsequentlyincreased.Doublingtheonce

dailydoseto2.5mgaftertwoweeksandthento5mgafterafurthertwoweeksisrecommended.

Inpatientswithdiabetesandatleastonecardiovascularrisk

Startingdose:

Therecommendedinitialdoseis2.5mgofByTriteoncedaily.

Titrationandmaintenancedose

Dependingonthepatient’stolerabilitytotheactivesubstance,thedoseissubsequentlyincreased.Doublingthedaily

doseto5mgByTriteafteroneortwoweeksandthento10mgByTriteafterafurthertwoorthreeweeksis

recommended.Thetargetdailydoseis10mg.

Inpatientswithnon-diabeticnephropathyasdefinedbymacroproteinuria3g/day.

Startingdose:

Therecommendedinitialdoseis1.25mgofByTriteoncedaily.

Titrationandmaintenancedose

Dependingonthepatient’stolerabilitytotheactivesubstance,thedoseissubsequentlyincreased.Doublingtheonce

dailydoseto2.5mgaftertwoweeksandthento5mgafterafurthertwoweeksisrecommended.

Symptomaticheartfailure

Startingdose

Inpatientsstabilizedondiuretictherapy,therecommendedinitialdoseis1.25mgdaily.

Titrationandmaintenancedose

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 2

administrationsperdayarepreferable.

Secondarypreventionafteracutemyocardialinfarctionandwithheartfailure

Startingdose

After48hours,followingmyocardialinfarctioninaclinicallyandhaemodynamicallystablepatient,thestartingdoseis

2.5mgtwicedailyforthreedays.Iftheinitial2.5mgdoseisnottoleratedadoseof1.25mgtwiceadayshouldbe

givenfortwodaysbeforeincreasingto2.5mgand5mgtwiceaday.Ifthedosecannotbeincreasedto2.5mgtwicea

daythetreatmentshouldbewithdrawn.

Seealsoposologyondiuretictreatedpatientsabove.

Titrationandmaintenancedose

Thedailydoseissubsequentlyincreasedbydoublingthedoseatintervalsofonetothreedaysuptothetarget

maintenancedoseof5mgtwicedaily.

Themaintenancedoseisdividedin2administrationsperdaywherepossible.

Ifthedosecannotbeincreasedto2.5mgtwiceadaytreatmentshouldbewithdrawn.Sufficientexperienceisstill

lackinginthetreatmentofpatientswithsevere(NYHAIV)heartfailureimmediatelyaftermyocardialinfarction.

Shouldthedecisionbetakentotreatthesepatients,itisrecommendedthattherapybestartedat1.25mgoncedailyand

thatparticularcautionbeexercisedinanydoseincrease.

Specialpopulations

Patientswithrenalimpairment

Dailydoseinpatientswithrenalimpairmentshouldbebasedoncreatinineclearance(seesection5.2):

-ifcreatinineclearanceis ≥60ml/min,itisnotnecessarytoadjusttheinitialdose(2.5mg/day);themaximal

dailydoseis10mg;

-ifcreatinineclearanceisbetween30-60ml/min,itisnotnecessarytoadjusttheinitialdose(2.5mg/day);the

maximaldailydoseis5mg;

-ifcreatinineclearanceisbetween10-30ml/min,theinitialdoseis1.25mg/dayandthemaximaldailydoseis5

-inhaemodialysedhypertensivepatients:ramiprilisslightlydialysable;theinitialdoseis1.25mg/dayandthe

maximaldailydoseis5mg;themedicinalproductshouldbeadministeredfewhoursafterhaemodialysisis

performed.

Patientswithhepaticimpairment(seesection5.2)

Inpatientswithhepaticimpairment,treatmentwithByTritemustbeinitiatedonlyunderclosemedicalsupervisionand

themaximumdailydoseis2.5mgByTrite.

Elderly

Initialdosesshouldbelowerandsubsequentdosetitrationshouldbemoregradualbecauseofgreaterchanceof

undesirableeffectsespeciallyinveryoldandfrailpatients.Areducedinitialdoseof1.25mgramiprilshouldbe

considered.

Paediatricpopulation

ByTriteisnotrecommendedforuseinchildrenandadolescentsbelow18yearsofageduetoinsufficientdataonsafety

andefficacy.

4.3Contraindications

Hypersensitivitytotheactivesubstance,toanyoftheexcipientsoranyotherACE

(AngiotensinConvertingEnzyme)inhibitors(seesection6.1)

Historyofangioedema(hereditary,idiopathicorduetopreviousangioedemawithACEinhibitorsorAIIRAs)

Extracorporealtreatmentsleadingtocontactofbloodwithnegativelychargedsurfaces(seesection4.5)

Significantbilateralrenalarterystenosisorrenalarterystenosisinasinglefunctioningkidney

and3 rd

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 3

Ramiprilmustnotbeusedinpatientswithhypotensiveorhaemodynamicallyunstablestates.

4.4Specialwarningsandprecautionsforuse

Specialpopulations

Pregnancy:ACEinhibitorssuchasramipril,orAngiotensinIIReceptorAntagonists(AIIRAs)shouldnotbeinitiated

duringpregnancy.UnlesscontinuedACEinhibitor/AIIRAstherapyisconsideredessential,patientsplanning

pregnancyshouldbechangedtoalternativeanti-hypertensivetreatmentswhichhaveanestablishedsafetyprofilefor

useinpregnancy.Whenpregnancyisdiagnosed,treatmentwithACEinhibitors/AIIRAsshouldbestopped

immediately,and,ifappropriate,alternativetherapyshouldbestarted(seesections4.3and4.6).

Patientsatparticularriskofhypotension

Patientswithstronglyactivatedrenin-angiotensin-aldosteronesystem

Patientswithstronglyactivatedrenin-angiotensin-aldosteronesystemareatriskofanacutepronouncedfallinblood

pressureanddeteriorationofrenalfunctionduetoACEinhibition,especiallywhenanACEinhibitorora

concomitantdiureticisgivenforthefirsttimeoratfirstdoseincrease.

Significantactivationofrenin-angiotensin-aldosteronesystemistobeanticipatedandmedicalsupervisionincluding

bloodpressuremonitoringisnecessary,forexamplein:

patientswithseverehypertension

patientswithdecompensatedcongestiveheartfailure

patientswithhaemodynamicallyrelevantleftventricularinfloworoutflowimpediment(e.g.stenosisofthe

aorticormitralvalve)

patientswithunilateralrenalarterystenosiswithasecondfunctionalkidney

patientsinwhomfluidorsaltdepletionexistsormaydevelop(includingpatientswithdiuretics)

patientswithlivercirrhosisand/orascites

patientsundergoingmajorsurgeryorduringanaesthesiawithagentsthatproducehypotension.

Generally,itisrecommendedtocorrectdehydration,hypovolaemiaorsaltdepletionbeforeinitiatingtreatment(in

patientswithheartfailure,however,suchcorrectiveactionmustbecarefullyweighedoutagainsttheriskofvolume

overload).

TransientorpersistentheartfailurepostMI

Patientsatriskofcardiacorcerebralischemiaincaseofacutehypotension

Theinitialphaseoftreatmentrequiresspecialmedicalsupervision.

Elderlypatients

Seesection4.2.

Surgery

Itisrecommendedthattreatmentwithangiotensinconvertingenzymeinhibitorssuchasramiprilshouldbe

discontinuedwherepossibleonedaybeforesurgery.

Monitoringofrenalfunction

Renalfunctionshouldbeassessedbeforeandduringtreatmentanddosageadjustedespeciallyintheinitialweeksof

treatment.Particularlycarefulmonitoringisrequiredinpatientswithrenalimpairment(seesection4.2).Thereisarisk

ofimpairmentofrenalfunction,particularlyinpatientswithcongestiveheartfailureorafterarenaltransplant.

Angioedema

AngioedemahasbeenreportedinpatientstreatedwithACEinhibitorsincludingramipril(seesection4.8).

Incaseofangioedema,ByTritemustbediscontinued.

Emergencytherapyshouldbeinstitutedpromptly.Patientshouldbekeptunderobservationforatleast12to24hours

anddischargedaftercompleteresolutionofthesymptoms.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 4

Thesepatientspresentedwithabdominalpain(withorwithoutnauseaorvomiting).

Anaphylacticreactionsduringdesensitization

Thelikelihoodandseverityofanaphylacticandanaphylactoidreactionstoinsectvenomandotherallergensare

increasedunderACEinhibition.AtemporarydiscontinuationofByTriteshouldbeconsideredpriortodesensitization.

Hyperkalaemia

HyperkalaemiahasbeenobservedinsomepatientstreatedwithACEinhibitorsincludingByTrite.Patientsatriskfor

developmentofhyperkalaemiaincludethosewithrenalinsufficiency,age(>70years),uncontrolleddiabetesmellitus,

orthoseusingpotassiumsalts,potassiumretainingdiureticsandotherplasmapotassiumincreasingactivesubstances,

orconditionssuchasdehydration,acutecardiacdecompensation,metabolicacidosis.Ifconcomitantuseoftheabove

mentionedagentsisdeemedappropriate,regularmonitoringofserumpotassiumisrecommended(seesection4.5).

Neutropenia/agranulocytosis

Neutropenia/agranulocytosis,aswellasthrombocytopeniaandanaemia,havebeenrarelyseenandbonemarrow

depressionhasalsobeenreported.Itisrecommendedtomonitorthewhitebloodcellcounttopermitdetectionofa

possibleleucopoenia.Morefrequentmonitoringisadvisedintheinitialphaseoftreatmentandinpatientswith

impairedrenalfunction,thosewithconcomitantcollagendisease(e.g.lupuserythematosusorscleroderma),andall

thosetreatedwithothermedicinalproductsthatcancausechangesinthebloodpicture(seesections4.5and4.8).

Ethnicdifferences

ACEinhibitorscausehigherrateofangioedemainblackpatientsthaninnonblackpatients.

AswithotherACEinhibitors,ramiprilmaybelesseffectiveinloweringbloodpressureinblackpeoplethaninnon

blackpatients,possiblybecauseofahigherprevalenceofhypertensionwithlowreninlevelintheblackhypertensive

population.

Cough

CoughhasbeenreportedwiththeuseofACEinhibitors.Characteristically,thecoughisnon-productive,persistentand

resolvesafterdiscontinuationoftherapy.ACEinhibitor-inducedcoughshouldbeconsideredaspartofthedifferential

diagnosisofcough.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Contra-indicatedcombinations

Extracorporealtreatmentsleadingtocontactofbloodwithnegativelychargedsurfacessuchasdialysisor

haemofiltrationwithcertainhigh-fluxmembranes(e.g.polyacrylonitrilmembranes)andlowdensitylipoprotein

apheresiswithdextransulphateduetoincreasedriskofsevereanaphylactoidreactions(seesection4.3).Ifsuch

treatmentisrequired,considerationshouldbegiventousingadifferenttypeofdialysismembraneoradifferentclass

ofantihypertensiveagent.

Precautionsforuse

Potassiumsalts,heparin,potassium-retainingdiureticsandotherplasmapotassiumincreasingactivesubstances

(includingAngiotensinIIantagonists,trimethoprim,tacrolimus,ciclosporin):Hyperkalaemiamayoccur,therefore

closemonitoringofserumpotassiumisrequired.

Antihypertensiveagents(e.g.diuretics)andothersubstancesthatmaydecreasebloodpressure(e.g.nitrates,tricyclic

antidepressants,anaesthetics,acutealcoholintake,baclofen,alfuzosin,doxazosin,prazosin,tamsulosin,terazosin):

Potentiationoftheriskofhypotensionistobeanticipated(seesection4.2fordiuretics)

Vasopressorsympathomimeticsandothersubstances(e.g.isoproterenol,dobutamine,dopamine,epinephrine)that

mayreducetheantihypertensiveeffectofByTrite:Bloodpressuremonitoringisrecommended.

Allopurinol,immunosuppressants,corticosteroids,procainamide,cytostaticsandothersubstancesthatmaychangethe

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 5

Lithiumsalts:ExcretionoflithiummaybereducedbyACEinhibitorsandthereforelithiumtoxicitymaybeincreased.

Lithiumlevelmustbemonitored.

Antidiabeticagentsincludinginsulin:Hypoglycaemicreactionsmayoccur.Bloodglucosemonitoringis

recommended.

Non-steroidalanti-inflammatorydrugsandacetylsalicylicacid:ReductionoftheantihypertensiveeffectofByTriteis

tobeanticipated.Furthermore,concomitanttreatmentofACEinhibitorsandNSAIDsmayleadtoanincreasedriskof

worseningofrenalfunctionandtoanincreaseinkalaemia.

4.6Fertility,pregnancyandlactation

ByTriteisnotrecommendedduringthefirsttrimesterofpregnancy(seesection4.4)andcontraindicatedduringthe

secondandthirdtrimestersofpregnancy(seesection4.3).

EpidemiologicalevidenceregardingtheriskofteratogenicityfollowingexposuretoACEinhibitorsduringthefirst

trimesterofpregnancyhasnotbeenconclusive;howeverasmallincreaseinriskcannotbeexcluded.Unlesscontinued

ACEinhibitortherapyisconsideredessential,patientsplanningpregnancyshouldbechangedtoalternativeanti-

hypertensivetreatmentswhichhaveanestablishedsafetyprofileforuseinpregnancy.Whenpregnancyisdiagnosed,

treatmentwithACEinhibitorsshouldbestoppedimmediately,and,ifappropriate,alternativetherapyshouldbestarted.

ACEinhibitor/AngiotensinIIReceptorAntagonist(AIIRA)therapyexposureduringthesecondandthirdtrimestersis

knowntoinducehumanfetotoxicity(decreasedrenalfunction,oligohydramnios,skullossificationretardation)and

neonataltoxicity(renalfailure,hypotension,hyperkalaemia).(Seealso5.3'Preclinicalsafetydata').Shouldexposure

toACEinhibitorhaveoccurredfromthesecondtrimesterofpregnancy,ultrasoundcheckofrenalfunctionandskullis

recommended.NewbornswhosemothershavetakenACEinhibitorsshouldbecloselyobservedforhypotension,

oliguriaandhyperkalaemia(seealsosections4.3and4.4).

Becauseinsufficientinformationisavailableregardingtheuseoframiprilduringbreastfeeding(seesection5.2),

ramiprilisnotrecommendedandalternativetreatmentswithbetterestablishedsafetyprofilesduringbreast-feedingare

preferable,especiallywhilenursinganewbornorpreterminfant.

4.7Effectsonabilitytodriveandusemachines

Someadverseeffects(e.g.symptomsofareductioninbloodpressuresuchasdizziness)mayimpairthepatient’s

abilitytoconcentrateandreactand,therefore,constituteariskinsituationswheretheseabilitiesareofparticular

importance(e.g.operatingavehicleormachinery).

Thiscanhappenespeciallyatthestartoftreatment,orwhenchangingoverfromotherpreparations.Afterthefirstdose

orsubsequentincreasesindoseitisnotadvisabletodriveoroperatemachineryforseveralhours.

4.8Undesirableeffects

Thesafetyprofileoframiprilincludespersistentdrycoughandreactionsduetohypotension.Seriousadversereactions

includeangioedema,hyperkalaemia,renalorhepaticimpairment,pancreatitis,severeskinreactionsand

neutropenia/agranulocytosis.

Adversereactionsfrequencyisdefinedusingthefollowingconvention:

Verycommon( ≥1/10);common(≥1/100to<1/10);uncommon(≥1/1,000to<1/100);

rare( ≥1/10,000to<1/1,000);veryrare(<1/10,000);

notknown(cannotbeestimatedfromtheavailabledata).

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 6

Common Uncommon Rare Veryrare Notknown

Cardiac

disorders Myocardial

ischaemia

including

angina

pectorisor

myocardial

infarction,

tachycardia,

arrhythmia,

palpitations,

oedema

peripheral

Bloodand

lymphatic

system

disorders Eosinophilia Whitebloodcell

countdecreased

(including

neutropeniaor

agranulocytosis),

redbloodcell

countdecreased,

haemoglobin

decreased,

plateletcount

Bonemarrow

failure,

pancytopenia,

haemolytic

anaemia

Nervoussystem

disorders Headache,

dizziness Vertigo,

paraesthesia,

ageusia,

dysgeusia, Tremor,balance

disorder Cerebral

ischaemia

including

ischaemic

strokeand

transient

ischaemic

attack,

psychomotor

skillsimpaired,

burning

sensation,

parosmia

Eyedisorders Visual

disturbance

including

blurredvision Conjunctivitis

Earand

labyrinth

disorders Hearing

impaired,

tinnitus

Respiratory,

thoracicand

mediastinal

disorders Non-productive

ticklingcough,

bronchitis,

sinusitis,

dyspnoea Bronchospasm

including

asthma

aggravated,

nasal

congestion

Gastrointestinal

disorders Gastrointestinal

inflammation,

digestive

disturbances,

abdominal Pancreatitis

(casesoffatal

outcomehave

beenvery

exceptionally Glossitis Aphtous

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 7

discomfort,

dyspepsia,

diarrhoea,

nausea,

vomiting reportedwith

inhibitors),

pancreatic

enzymes

increased,

smallbowel

angioedema,

abdominal

painupper

including

gastritis,

constipation,

drymouth

Renaland

urinary

disorders Renal

impairment

including

renalfailure

acute,urine

output

increased,

worseningofa

pre-existing

proteinuria,

bloodurea

increased,

blood

creatinine

increased

Skinand

subcutaneous

tissuedisorders Rashin

particular

maculo-papular Angioedema;

very

exceptionally,

theairway

obstruction

resultingfrom

angioedema

mayhavea

fataloutcome;

pruritus,

Exfoliative

dermatitis,

urticaria,

onycholysis, Photosensitivity

reaction Toxic

epidermal

necrolysis,

Stevens-

Johnson

syndrome,

erythema

multiforme,

pemphigus,

psoriasis

aggravated,

dermatitis

psoriasiform,

pemphigoidor

lichenoid

exanthemaor

enanthema,

alopecia

Musculoskeletal

andconnective

tissuedisorders Musclespasms,

myalgia Arthralgia

Metabolismand

nutrition

disorders Blood

potassium

increased Anorexia,

decreased

appetite, Bloodsodium

decreased

Vascular

disorders Hypotension,

orthostatic Flushing Vascular

stenosis, Raynaud’s

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 8

4.9Overdose

SymptomsassociatedwithoverdosageofACEinhibitorsmayincludeexcessiveperipheralvasodilatation(withmarked

hypotension,shock),bradycardia,electrolytedisturbances,andrenalfailure.Thepatientshouldbecloselymonitored

andthetreatmentshouldbesymptomaticandsupportive.Suggestedmeasuresincludeprimarydetoxification(gastric

lavage,administrationofadsorbents)andmeasurestorestorehaemodynamicstability,including,administrationof

alpha1adrenergicagonistsorangiotensinII(angiotensinamide)administration.Ramiprilat,theactivemetaboliteof

ramiprilispoorlyremovedfromthegeneralcirculationbyhaemodialysis.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Pharmacotherapeuticgroup:ACEInhibitors,plain,ATCcodeC09AA05.

Mechanismofaction

Ramiprilat,theactivemetaboliteoftheprodrugramipril,inhibitstheenzymedipeptidylcarboxypeptidaseI(synonyms:

angiotensin-convertingenzyme;kininaseII).InplasmaandtissuethisenzymecatalysestheconversionofangiotensinI

totheactivevasoconstrictorsubstanceangiotensinII,aswellasthebreakdownoftheactivevasodilatorbradykinin.

bloodpressure

decreased,

syncope hypoperfusion,

vasculitis

General

disordersand

administration

siteconditions Chestpain,

fatigue Pyrexia Asthenia

Immunesystem

disorders Anaphylactic

anaphylactoid

reactions,

antinuclear

antibody

increased

Hepatobiliary

disorders Hepatic

enzymes

and/or

bilirubin

conjugated

increased, Jaundice

cholestatic,

hepatocellular

damage Acutehepatic

failure,

cholestaticor

cytolytic

hepatitis(fatal

outcomehas

beenvery

exceptional).

Reproductive

systemand

breastdisorders Transient

erectile

impotence,

libido

decreased Gynaecomastia

Psychiatric

disorders Depressed

mood,

anxiety,

nervousness,

restlessness,

sleepdisorder

including

somnolence Confusional

state Disturbancein

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 9

SinceangiotensinIIalsostimulatesthereleaseofaldosterone,ramiprilatcausesareductioninaldosteronesecretion.

TheaverageresponsetoACEinhibitormonotherapywaslowerinblack(Afro-Caribbean)hypertensivepatients

(usuallyalow-reninhypertensivepopulation)thaninnon-blackpatients.

Pharmacodynamiceffects

Antihypertensiveproperties:

Administrationoframiprilcausesamarkedreductioninperipheralarterialresistance.Generally,therearenomajor

changesinrenalplasmaflowandglomerularfiltrationrate.Administrationoframipriltopatientswithhypertension

leadstoareductioninsupineandstandingbloodpressurewithoutacompensatoryriseinheartrate.

Inmostpatientstheonsetoftheantihypertensiveeffectofasingledosebecomesapparent1to2hoursafteroral

administration.Thepeakeffectofasingledoseisusuallyreached3to6hoursafteroraladministration.The

antihypertensiveeffectofasingledoseusuallylastsfor24hours.

Themaximumantihypertensiveeffectofcontinuedtreatmentwithramiprilisgenerallyapparentafter3to4weeks.It

hasbeenshownthattheantihypertensiveeffectissustainedunderlongtermtherapylasting2years.

Abruptdiscontinuationoframiprildoesnotproducearapidandexcessivereboundincreaseinbloodpressure.

Heartfailure:

Inadditiontoconventionaltherapywithdiureticsandoptionalcardiacglycosides,ramiprilhasbeenshowntobe

effectiveinpatientswithfunctionalclassesII-IVoftheNew-YorkHeartAssociation.Thedrughadbeneficialeffects

oncardiachaemodynamics(decreasedleftandrightventricularfillingpressures,reducedtotalperipheralvascular

resistance,increasedcardiacoutputandimprovedcardiacindex).Italsoreducedneuroendocrineactivation.

Clinicalefficacyandsafety

Cardiovascularprevention/Nephroprotection;

Apreventiveplacebo-controlledstudy(theHOPE-study),wascarriedoutinwhichramiprilwasaddedtostandard

therapyinmorethan9,200patients.Patientswithincreasedriskofcardiovasculardiseasefollowingeither

atherothromboticcardiovasculardisease(historyofcoronaryheartdisease,strokeorperipheralvasculardisease)or

diabetesmellituswithatleastoneadditionalriskfactor(documentedmicroalbuminuria,hypertension,elevatedtotal

cholesterollevel,lowhigh-densitylipoproteincholesterollevelorcigarettesmoking)wereincludedinthestudy.

Thestudyshowedthatramiprilstatisticallysignificantlydecreasestheincidenceofmyocardialinfarction,deathfrom

cardiovascularcausesandstroke,aloneandcombined(primarycombinedevents).

TheHOPEstudy:Mainresults

Ramipril Placebo relativerisk

(95% confidence

interval) p-value

Allpatients n=4,645 N=4,652

Primarycombinedevents 14.0 17.8 0.78(0.70-0.86) <0.001

Myocardialinfarction 9.9 12.3 0.80(0.70-0.90) <0.001

Death from cardiovascular

causes 6.1 8.1 0.74(0.64-0.87) <0.001

Stroke 3.4 4.9 0.68(0.56-0.84) <0.001

Secondaryendpoints

Deathfromanycause 10.4 12.2 0.84(0.75-0.95) 0.005

NeedforRevascularisation 16.0 18.3 0.85(0.77-0.94) 0.002

Hospitalisation for unstable

angina 12.1 12.3 0.98(0.87-1.10) NS

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 10

TheMICRO-HOPEstudy,apredefinedsubstudyfromHOPE,investigatedtheeffectoftheadditionoframipril10mg

tothecurrentmedicalregimenversusplaceboin3,577patientsatleast ≥55yearsold(withnoupperlimitofage),with

amajorityoftype2diabetes(andatleastanotherCVriskfactor),normotensiveorhypertensive.

Theprimaryanalysisshowedthat117(6.5%)participantsonramipriland149(8.4%)onplacebodevelopedovert

nephropathy,whichcorrespondstoaRRR24%;95%CI[3-40],p=0.027.

TheREINstudy,amulticenterrandomized,double-blindparallelgroup,placebo-controlledstudyaimedatassessing

theeffectoftreatmentwithramiprilontherateofdeclineofglomerularfunctionrate(GFR)in352normotensiveor

hypertensivepatients(18-70yearsold)sufferingfrommild(i.e.meanurinaryproteinexcretion>1and<3g/24h)or

severeproteinuria( ≥3g/24h)duetochronicnon-diabeticnephropathy.Bothsubpopulationswereprospectively

stratified.

Themainanalysisofpatientswiththemostsevereproteinuria(stratumprematurelydisruptedduetobenefitinramipril

group)showedthatthemeanrateofGFRdeclinepermonthwaslowerwithramiprilthanwithplacebo;-0.54(0.66)vs.

-0.88(1.03)ml/min/month,p=0.038.Theintergroupdifferencewasthus0.34[0.03-0.65]permonth,andaround4

ml/min/year;23.1%ofthepatientsintheramiprilgroupreachedthecombinedsecondaryendpointofdoublingof

baselineserumcreatinineconcentrationand/orend-stagerenaldisease(ESRD)(needfordialysisorrenal

transplantation)vs.45.5%intheplacebogroup(p=0.02).

Secondarypreventionafteracutemyocardialinfarction

TheAIREstudyincludedmorethan2,000patientswithtransient/persistentclinicalsignsofheartfailureafter

documentedmyocardialinfarction.Theramipriltreatmentwasstarted3to10daysaftertheacutemyocardial

infarction.Thestudyshowedthatafteranaveragefollow-uptimeof15monthsthemortalityinramipril-treated

patientswas16.9%andintheplacebotreatedpatientswas22.6%.Thismeansanabsolutemortalityreductionof5.7

%andarelativeriskreductionof27%(95%CI[11-40%]).

5.2Pharmacokineticproperties

PharmacokineticsandMetabolismAbsorption

Followingoraladministrationramiprilisrapidlyabsorbedfromthegastrointestinaltract:peakplasmaconcentrations

oframiprilarereachedwithinonehour.Basedonurinaryrecovery,theextentofabsorptionisatleast56%andisnot

significantlyinfluencedbythepresenceoffoodinthegastrointestinaltract.Thebioavailabilityoftheactivemetabolite

ramiprilatafteroraladministrationof2.5mgand5mgramiprilis45%.

Peakplasmaconcentrationsoframiprilat,thesoleactivemetaboliteoframiprilarereached2-4hoursafterramipril

intake.Steadystateplasmaconcentrationsoframiprilatafteroncedailydosingwiththeusualdosesoframiprilare

reachedbyaboutthefourthdayoftreatment.

Distribution

Theserumproteinbindingoframiprilisabout73%andthatoframiprilatabout56%.

Metabolism

Ramiprilisalmostcompletelymetabolisedtoramiprilat,andtothediketopiperazineester,thediketopiperazineacid,

andtheglucuronidesoframiprilandramiprilat.

Elimination

Excretionofthemetabolitesisprimarilyrenal.

Plasmaconcentrationsoframiprilatdeclineinapolyphasicmanner.Becauseofitspotent,saturablebindingtoACE

andslowdissociationfromtheenzyme,ramiprilatshowsaprolongedterminaleliminationphaseatverylowplasma

Complicationsrelatedtodiabetes 6.4 7.6 0.84(0.72-0.98) 0.03 Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 11

Aftermultipleonce-dailydosesoframipril,theeffectivehalf-lifeoframiprilatconcentrationswas13-17hoursforthe

5-10mgdosesandlongerforthelower1.25-2.5mgdoses.Thisdifferenceisrelatedtothesaturablecapacityofthe

enzymetobindramiprilat.

Asingleoraldoseoframiprilproducedanundetectableleveloframiprilanditsmetaboliteinbreastmilk.Howeverthe

effectofmultipledosesisnotknown.

Patientswithrenalimpairment(seesection4.2)

Renalexcretionoframiprilatisreducedinpatientswithimpairedrenalfunction,andrenalramiprilatclearanceis

proportionallyrelatedtocreatinineclearance.Thisresultsinelevatedplasmaconcentrationsoframiprilat,which

decreasemoreslowlythaninsubjectswithnormalrenalfunction.

Patientswithhepaticimpairment(seesection4.2)

Inpatientswithimpairedliverfunction,themetabolismoframipriltoramiprilatwasdelayed,duetodiminished

activityofhepaticesterases,andplasmaramiprillevelsinthesepatientswereincreased.Peakconcentrationsof

ramiprilatinthesepatients,however,arenotdifferentfromthoseseeninsubjectswithnormalhepaticfunction.

5.3Preclinicalsafetydata

Oraladministrationoframiprilhasbeenfoundtobedevoidofacutetoxicityinrodentsanddogs.

Studiesinvolvingchronicoraladministrationhavebeenconductedinrats,dogsandmonkeys.Indicationsofplasma

electrolyteshiftsandchangesinbloodpicturehavebeenfoundinthe3species.

Asanexpressionofthepharmacodynamicactivityoframipril,pronouncedenlargementofthejuxtaglomerular

apparatushasbeennotedinthedogandmonkeyfromdailydosesof250mg/kg/d.Rats,dogsandmonkeystolerated

dailydosesof2,2.5and8mg/kg/drespectivelywithoutharmfuleffects.

Reproductiontoxicologystudiesintherat,rabbitandmonkeydidnotdiscloseanyteratogenicproperties.Fertilitywas

notimpairedeitherinmaleorinfemalerats.

Theadministrationoframipriltofemaleratsduringthefetalperiodandlactationproducedirreversiblerenaldamage

(dilatationoftherenalpelvis)intheoffspringatdailydosesof50mg/kgbodyweightorhigher.

Extensivemutagenicitytestingusingseveraltestsystemshasyieldednoindicationthatramiprilpossessesmutagenicor

genotoxicproperties.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Core

Pregelatinisedstarch

Calciumphosphate

Magnesiumhydroxide

Collodialanhydroussilica

Magnesiumstearate

CapsuleShell

Titaniumdioxide(E171)

Yellowironoxide(E172)

Gelatin

Printingink(blackprintinginkSW–9008/SW–9009)contains:shellac,dehydratedalcohol,n-butylalcohol,purified

water,strongammoniasolution,potassiumhydroxide,propyleneglycol,blackironoxide(E172),andisopropyl

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 12

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

18months.

6.4Specialprecautionsforstorage

Donotstoreabove25°C.

Storeintheoriginalpackageinordertoprotectfrommoisture.

6.5Natureandcontentsofcontainer

TransparentPVC/Aclar254µm/51µmandaluminium20µmfoil,packof28,30and50capsules.

Notallpacksizesmaybemarketed

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Nospecialrequirements.

7MARKETINGAUTHORISATIONHOLDER

HelsinnBirexTherapeuticsLtd

Damastown

Mulhuddart

Dublin15

Ireland

8MARKETINGAUTHORISATIONNUMBER

PA915/9/1

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateofauthorisation:22April2005

Dateoflastrenewal:22April2010

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 14/04/2011 CRN 2089631 page number: 13